Download PDF
Pharmacopsychiatry 2024; 57(02): 78-81
DOI: 10.1055/a-2262-8297
Letter to the Editor

Risperidone-Induced Leukoneutropenia: Evidence from a Positive Rechallenge and Review of the Literature

Dhouha Sahnoun 
1   Department of Pharmacovigilance, University of Sousse, Tunisia
,
Ahlem Ghanmi
2   Department of Psychiatry, Farhat Hachad Hospital, Sousse University, Tunisia
,
Soumaya Gazzeh
2   Department of Psychiatry, Farhat Hachad Hospital, Sousse University, Tunisia
,
Bochra Saguem
2   Department of Psychiatry, Farhat Hachad Hospital, Sousse University, Tunisia
,
Raoudha Slim
1   Department of Pharmacovigilance, University of Sousse, Tunisia
,
Jaafar Nakhli
2   Department of Psychiatry, Farhat Hachad Hospital, Sousse University, Tunisia
,
Chaker Ben Salem
1   Department of Pharmacovigilance, University of Sousse, Tunisia
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Antipsychotics can cause hematologic disorders, and they can have life-threatening consequences. Risperidone, less commonly associated with hematologic adverse effects, is an atypical antipsychotic medication used to treat conditions such as schizophrenia, bipolar disorder and irritability associated with autism. While risperidone primarily affects the central nervous system, it can have some hematologic adverse effects, although these are relatively rare. It is crucial to note that these side effects are not common, and most people taking risperidone do not experience hematologic disorders. The reporting of such disorders may be more frequent with clozapine compared to other atypical antipsychotics because clozapine treatment necessitates regular hematological monitoring [1].



Publication History

Received: 07 January 2024
Received: 01 February 2024

Accepted: 05 February 2024

Article published online:
12 March 2024

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Tiihonen J, Tanskanen A, Bell JS. et al. Long-term treatment with clozapine and other antipsychotic drugs and the risk of haematological malignancies in people with schizophrenia: a nationwide case-control and cohort study in Finland. Lancet Psychiatry 2022; 9: 353-362
    CrossrefPubMedGoogle Scholar
  • 2 Naranjo CA, Busto U, Sellers EM. et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-245
    CrossrefPubMedGoogle Scholar
  • 3 Oyesanmi O, Kunkel EJ, Monti DA. et al. Hematologic side effects of psychotropics. Psychosomatics. 1999; 40: 414-421
    CrossrefPubMedGoogle Scholar
  • 4 Stübner S, Grohmann R, Engel R. et al. Blood dyscrasias induced by psychotropic drugs. Pharmacopsychiatry 2004; 37: S70-S78
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Meylan C, Bondolfi G, Aubert AC. et al. Reversible neutropenia during a cold: possible involvement of risperidone? A case report. Eur Neuropsychopharmacol 1995; 5: 1-2
    CrossrefPubMedGoogle Scholar
  • 6 Bondolfi G, Morena P, Dascal DR. et al. Risperidone and reversible neutropenia: a negative rechallenge. Eur Neuropsychopharmacol J 1996; 6: 257
    CrossrefPubMedGoogle Scholar
  • 7 Dernovsek Z, Tavcar R. Risperidone-induced leucopenia and neutropenia. Br J Psychiatry 1997; 171: 393-394
    CrossrefPubMedGoogle Scholar
  • 8 Etain B, Roubaud L, Le Heuzey MF. et al. A case of leukopenia in treatment with risperidone in an adolescent. L’Encephale 2000; 26: 81-84
    PubMedGoogle Scholar
  • 9 Sluys M, Güzelcan Y, Casteelen G. et al. Risperidone-induced leucopenia and neutropenia: a case report. Eur Psychiatry J Assoc Eur Psychiatr 2004; 19: 117
    CrossrefPubMedGoogle Scholar
  • 10 López Altimiras FX, Muñoz Rodríguez FJ, Escoté Llobet S. Leukopenia associated to the use of risperidone: a case report and review of the literature. Rev Clin Esp 2006; 206: 162-163
    CrossrefPubMedGoogle Scholar
  • 11 Uzun S, Kozumplik O, Jakovljević M. et al Leukopenia during therapy with risperidone long-acting injectable: two case reports. J Clin Psychopharmacol déc 2008; 28: 713-714
    CrossrefPubMedGoogle Scholar
  • 12 Erbey F, Ruzgar H, Okur M. The risperidone-induced leukopenia and neutropenia: A case at 7 years old. Anadolu Psikiyatri Dergisi 2011; 12: 243-244
    PubMedGoogle Scholar
  • 13 Tseng CC. Neutropenia during risperidone treatment. J Neuropsychiatry Clin Neurosci 2011; 23: E19
    CrossrefPubMedGoogle Scholar
  • 14 Manfredi G, Solfanelli A, Dimitri G. et al. Risperidone-induced leukopenia: a case report and brief review of literature. Gen Hosp Psychiatry 2013; 35: 102.e3-6
    CrossrefPubMedGoogle Scholar
  • 15 Farrell H, Eastman P. Risperidone-induced neutropenia: an adverse side effect in the palliative management of delirium in a patient with lymphoma. BMJ Support Palliat Care 2013; 3: 4-5
    CrossrefPubMedGoogle Scholar
  • 16 Raj V, Druitt T, Purushothaman S. et al. Risperidone/paliperidone induced neutropenia and lymphopenia. Aust N Z J Psychiatry 2013; 47: 291-292
    CrossrefPubMedGoogle Scholar
  • 17 Hou YC, Lai CH. The relief of leukocytopenia within 1 month after switching risperidone to amisulpride. J Neuropsychiatry Clin Neurosci 2014; 26: E40-E41
    CrossrefPubMedGoogle Scholar
  • 18 Kattalai Kailasam V, Chima V, Nnamdi U. et al. Risperidone-induced reversible neutropenia. Neuropsychiatr Dis Treat 2017; 13: 1975-1977
    CrossrefPubMedGoogle Scholar
  • 19 Woon LSC, Tee CK, Gan LLY. et al. Olanzapine-induced and Risperidone-induced Leukopenia: A Case of Synergistic Adverse Reaction?. J Psychiatr Pract 2018; 24: 121-124
    CrossrefPubMedGoogle Scholar
  • 20 McGuire PR, Coplan BM, Puri S. Successful Long-Acting Paliperidone Treatment Following Reversible Risperidone-Induced Neutropenia. Prim Care Companion CNS Disord 2020; 22: 19l02516
    CrossrefPubMedGoogle Scholar
  • 21 Atolagbe A, Nkemjika S, Popoola O. et al. Risperidone-Induced Neutropenia in a Schizophrenic Patient: A Case Report and Literature Review. Case Rep Psychiatry 2021; 2021: 3980872
    PubMedGoogle Scholar
  • 22 Coşar B, Taner ME, Eser HY. et al. Does switching to another antipsychotic in patients with clozapine-associated granulocytopenia solve the problem? Case series of 18 patients. J ClinPsychopharmacol 2011; 31: 169-173
    CrossrefPubMedGoogle Scholar
  • 23 Flanagan RJ, Dunk L. Haematological toxicity of drugs used in psychiatry. Human Psychopharmacology: Clinical and Experimental 2008; 23: S27-S41
    CrossrefPubMedGoogle Scholar